使用抗硬化蛋白抗体进行治疗以刺激下颌骨形成。
Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation.
作者信息
Tamplen Matthew, Fowler Tristan, Markey Jeffery, Knott P Daniel, Suva Larry J, Alliston Tamara
机构信息
Department of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, California.
Department of Orthopedic Surgery, University of California, San Francisco, California.
出版信息
Head Neck. 2018 Jul;40(7):1453-1460. doi: 10.1002/hed.25128. Epub 2018 Mar 9.
BACKGROUND
Anti-Sclerostin antibody (Scl-Ab) is a promising new bone anabolic therapy. Although anti-Scl-Ab stimulates bone formation and repair in the appendicular and axial skeleton, its efficacy in the craniofacial skeleton is still poorly understood.
METHODS
Using an established model of Down syndrome-dependent bone deficiency, 10 Ts65Dn mice and 10 wild-type mice were treated weekly via i.v. tail vein injection with vehicle or anti-Sclerostin for 3 weeks and euthanized 1 week after.
RESULTS
Wild-type mice treated with the anti-Scl-Ab had increased mandibular bone, trabecular thickness, and alveolar height compared with controls. Anti-Scl-Ab increased Ts65Dn mandibular bone parameters such that they were statistically indistinguishable from those in vehicle-treated wild-type mandibles.
CONCLUSION
Treatment with anti-Scl-Ab significantly increased mandibular bone mass and alveolar height in wild type mice and normalized mandibular bone mass and alveolar height in Ts65Dn mice. The anti-Scl-Ab therapy represents a novel method for increasing mandibular bone formation.
背景
抗硬化蛋白抗体（Scl-Ab）是一种很有前景的新型骨合成代谢疗法。尽管抗Scl-Ab能刺激四肢骨骼和中轴骨骼的骨形成与修复，但其在颅面骨骼中的疗效仍知之甚少。
方法
利用已建立的唐氏综合征相关骨缺损模型，10只Ts65Dn小鼠和10只野生型小鼠每周通过尾静脉注射载体或抗硬化蛋白进行治疗，持续3周，并在1周后实施安乐死。
结果
与对照组相比，接受抗Scl-Ab治疗的野生型小鼠下颌骨、小梁厚度和牙槽高度增加。抗Scl-Ab增加了Ts65Dn小鼠的下颌骨参数，使其在统计学上与接受载体治疗的野生型下颌骨无差异。
结论
抗Scl-Ab治疗显著增加了野生型小鼠的下颌骨质量和牙槽高度，并使Ts65Dn小鼠的下颌骨质量和牙槽高度恢复正常。抗Scl-Ab疗法是一种增加下颌骨形成的新方法。
Zotero 插件